CD5-positive DLBCL are typically ABC [42, 48], show recurrent gains of 16p and losses of 1p and of 9q21 [36, 49], the latter being involved in chemoresistance [37], and display downregulation of extracellular matrix-related genes and upregulation of neurological function-related genes [48]. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.